ACS Pharmacology & Translational Science is planning to publish a Special Issue titled “Innovation and Discovery in Cardiovascular Biology” in October 2019, headed up by Associate Editor Kathleen M. Caron, Professor, and Chair of the Department of Cell Biology and Physiology at the University of North Carolina, Chapel Hill School of Medicine. She invites everyone doing research in this area to submit a manuscript by July 15, 2019.

“I hope those of you with breakthrough discoveries in cardiovascular biology will respond to this call for papers and submit a manuscript for consideration,” Professor Caron says. “We are particularly interested in receiving manuscripts that provide bridges between pharmacological sciences and mechanisms of cardiovascular pathophysiology.”

Submit your latest research on Innovation and Discovery in Cardiovascular Biology.

What to Submit—Deadline: July 15, 2019

Professor Caron says the editorial team is looking forward to receiving a diverse mix of manuscripts that fall within the broad discipline of cardiovascular biology. Their goal is to highlight several of the most recent technological and conceptual breakthroughs that elucidate mechanistic pathways of pathophysiology.

Areas of particular interest include:

• Single-cell analysis of cardiovascular organs in health and disease
• Endothelial cell heterogeneity in specialized vascular beds
• Regenerative potential and pathways
• Regulation and consequences of sex differences
• Rare diseases of cardiovascular dysfunction and metabolism

“We are particularly interested in receiving manuscripts that focus on therapeutic targets,” Professor Caron says. “In this regard, manuscripts that describe foundational discoveries are also encouraged.”

Articles, Letters, Reviews, Perspectives, and Viewpoints are all welcome. For details on requirements for each manuscript type, please consult the Author Guidelines. You can also find the entire ACS Pharmacology & Translational Science scope below.

Learn more about why you should publish your research with ACS Pharmacology & Translational Science.

The journal’s editors give priority to studies that fully integrate basic pharmacological and/or biochemical findings into physiological processes that have translational potential in a broad range of biomedical disciplines. Therefore, studies that employ a complementary blend of in vitro and in vivo systems are of particular interest, but they will consider all innovative research with articulated translational relevance.

If you’re not sure if your research is within scope, please email the journal’s editorial team at eic@ptsci.acs.org for feedback.

Submit your latest research on Innovation and Discovery in Cardiovascular Biology.